Legislation governing the US incentive scheme for neglected diseases needs to be amended, urges MSF

BMJ. 2014 Sep 30:349:g5861. doi: 10.1136/bmj.g5861.

Authors

Jennifer Reid¹, Julien Potet², Katy Athersuch³, Maisy Grovestock³, Judit Rius Sanjuan⁴

Affiliations

¹ Médecins Sans Frontières-Access Campaign, 333 7th Avenue, 2nd Floor, New York, NY 10001, USA Jennifer.Reid@newyork.msf.org.
² Médecins Sans Frontières-Access Campaign, 8 Rue Saint Sabin, 75011 Paris, France.
³ Médecins Sans Frontières-Access Campaign, Rue de Lausanne 78, CH-1211 Geneva 21, Switzerland.
⁴ Médecins Sans Frontières-Access Campaign, 333 7th Avenue, 2nd Floor, New York, NY 10001, USA.

PMID: 25269564
DOI: 10.1136/bmj.g5861

No abstract available

Publication types

Letter

MeSH terms

Biomedical Research / legislation & jurisprudence*
Humans
Medical Missions
Motivation
Neglected Diseases / therapy*
United States